Business Context and Reporting Period
This Form 8-K is a current report filed by CF Finance Acquisition Corp. III ("CF III") on May 3, 2021, regarding events occurring on April 30, 2021. The filing details amendments to the proposed merger agreement between CF III and AEye, Inc. ("AEye"). CF III is a special purpose acquisition company (SPAC) listed on the Nasdaq Stock Market, while AEye is a Delaware corporation developing autonomous driving technology.
Key Financial Metrics and Transaction Terms
The filing focuses on the restructuring of the merger consideration and the extension of the SPAC's business combination deadline. Key financial terms include:
- Merger Consideration: The aggregate merger consideration (excluding the exercise price of in-the-money options and warrants) was reduced from $1.9 billion to $1.52 billion.
- Trust Account Extension: The Sponsor deposited an additional $0.10 per share into CF III's trust account (the "First Extension Funding"), bringing the total to $10.10 per share.
- Debt Instrument: CF III issued a non-interest bearing, unsecured promissory note to the Sponsor in connection with the extension funding.
- Warrant Exercise Price: Redeemable warrants are exercisable for Class A common stock at $11.50 per share.
The filing does not provide specific revenue, profit, cash flow, or margin data for AEye or CF III, as this is a transactional report rather than a periodic financial statement.
Material Changes Versus Prior Period
The primary material change disclosed is the amendment to the Original Merger Agreement dated February 17, 2021. The most significant alteration is the reduction in the total merger consideration by approximately $380 million (from $1.9 billion to $1.52 billion). Additionally, the deadline for consummating the initial business combination was extended from May 17, 2021, to September 17, 2021, with a provision for a further extension to January 17, 2022, contingent on additional funding by the Sponsor.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook: The filing reaffirms the commitment to the merger through an Amended and Restated Stockholder Support Agreement, where key AEye stockholders agreed to vote in favor of the transaction. The Sponsor has committed to funding further extensions if necessary to close the deal by January 17, 2022.
Risks and Contingencies: The filing includes extensive forward-looking statements and risk factors, including:
- Failure to complete the transaction in a timely manner or at all.
- Inability to satisfy conditions for consummation, such as stockholder approval and minimum trust account balances post-redemption.
- Failure to complete PIPE (Private Investment in Public Equity) investments.
- Disruption to AEye's business operations and employee retention.
- Intellectual property enforceability and potential infringement claims.
- Impact of the COVID-19 pandemic on economic uncertainty and business plans.
Important Facts for Investor Verification
- Verify the final valuation of AEye based on the reduced $1.52 billion merger consideration.
- Confirm the status of the PIPE investments and whether they have been secured to support the transaction.
- Monitor the trust account balance and potential redemptions by public stockholders that could impact the minimum cash requirement for closing.
- Review the upcoming Form S-4 registration statement and proxy statement/prospectus for detailed financial projections and risk factors.
- Assess the likelihood of the transaction closing before the September 17, 2021, deadline or the extended January 17, 2022, date.